Progressive genetic aberrations detected by comparative genomic hybridization in squamous cell cervical cancer by Allen, D G et al.
Cervical cancer remains a major health problem amongst women
world-wide. Although the incidence is declining in industrialized
nations, the disease remains the most common cause of cancer
death in developing countries. Infection with oncogenic genotypes
of human papillomavirus (HPV) is the single most important
known factor in the pathogenesis of cervical cancer and its precur-
sors (zur Hausen, 1976; Liaw et al, 1999). The process of carcino-
genesis is dependent on HPV E6 and E7 genes, which bind with
the human p53 and Rb tumour suppressor gene products, respec-
tively, inactivating their function in cell cycle regulation (Durst
et al, 1987). However, many women have been exposed to HPV
without developing premalignant changes or cervical cancer,
which emphasizes the probable involvement of other genetic or
epigenetic events essential for tumour progression. 
Comparative genomic hybridization (CGH) is a powerful tool in
the study of cancer that has fast gained recognition for its ability to
scan an entire genome for chromosomal losses or gains. This is
achieved by measuring DNA copy number changes, which are
mapped to chromosome regions. Chromosome regions gained or
lost may harbour oncogenes or tumour suppressor genes, respec-
tively. Only a few studies of CGH in pre-invasive and invasive
cervical cancer have been published (Heselmeyer et al, 1996,
1997; Aubele et al, 1998; Kirchhoff et al, 1999; Dellas et al, 1999).
Cervical intraepithelial neoplasia grade 3 (CIN 3) and invasive
cervical carcinomas have shown similar non-random changes, but
quantitatively more changes have been seen in invasive carci-
nomas (Heselmeyer et al, 1996, 1997; Kirchhoff et al, 1999). In a
recent study, DNA losses of chromosome 18q and 11p, together
with an increased number of overall losses, were associated with
poor prognosis in clinical stage 1b invasive cancers in the absence
of lymph node metastases (Dellas et al, 1999). In other tumours,
such as breast and kidney cancer, a high number of DNA losses
have been associated with poor prognosis (Isola et al, 1995; Moch
et al, 1996). Thus it is possible that CGH analysis may indicate
prognosis in cancers of the cervix, leading to improved planning of
patient management. 
In this study, we analysed 37 cases of HPV-typed, clinical stage
1b squamous cell carcinomas of the cervix, with a minimum of 5
years follow-up. 20 cases were from women without lymph node
metastases and 17 from women with lymph node metastases. The
clinical outcome of stage-matched patients with and without
lymph node metastases is known to vary (Martinbeau et al, 1982).
Hence, we performed CGH analysis of the primary cervical
tumours, as well as the matched lymph node metastases, to deter-
mine specific gains and losses associated with both lymph node
status and survival. 
MATERIALS AND METHODS 
Patients attending the Mercy Hospital for Women for FIGO stage
1b squamous cell carcinoma of the cervix and treated with radical
hysterectomy and pelvic lymphadenectomy, between 1986 and
1994, were considered for this study. (FIGO 1b is defined as carci-
noma confined to the cervix and greater than 7 mm horizontal
dimension and/or 5 mm in depth of invasion, with or without
regional lymph node metastases. The equivalent classification is
T1b; N0; M0 for cases without regional metastases and T1b; N1;
M0 for those with regional metastases.) The first 20 patients
without lymph node metastases and 17 patients with lymph node
metastases were selected from the database. Follow-up data for a
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stage and lymph node metastasis, no other prognostic factors were
considered for selection. Clinical details of recurrences and patient
status were obtained from the patient’s record. Pathologic review
was performed and the histologic type and tumour grades were
recorded. 
CGH methods 
CGH analysis was performed on the primary cervical tumours as
well as the lymph nodes containing metastases. Areas of interest
(2–3 mm2) were microdissected from methyl green-stained
paraffin-embedded, formalin-fixed tissue sections with a 21 gauge
needle and placed into proteinase K digestion buffer. Reference
control DNAs were extracted from peripheral blood lymphocytes
using a Progenome kit (Progen). DOP-PCR was performed on the
tissue lysate as previously described (Kuukasjarvi et al, 1997;
Telenius et al, 1992). Amplified DNA samples were labelled by
nick translation using the Bionick labelling system (Life
Technologies). The probe was hybridized to normal metaphase
spreads for 3 days at 37˚C. Tumour samples were labelled with
Spectrum Red and hybridized with biotin labelled reference DNA,
or digoxigenin and hybridized with Spectrum Green labelled refer-
ence DNA to control for differences in hybridization by the
different fluorochromes. Following washing, biotinylated DNA
was detected by streptavidin-conjugated fluorescein isothiocyanate
(FITC) (Vector Laboratories) and digoxigenin-labelled DNA
by mouse-anti-digoxigenin antibody conjugated to rhodamine
(TRITC) (Boehringer-Mannheim). Samples were counterstained
with 4,6-diamino-2-phenylindole (DAPI) in phenyldiamine
antifade solution. Each CGH experiment included at least one
normal lymph node DNA as a negative control. Images were
captured using a Grundig FA87 digital video camera mounted on a
Zeiss Axioplan2 epifluorescent microscope equipped with single-
band excitation filters for each fluorochrome mounted in a
computer controlled Ludl filter wheel. Images were analysed with
Quips CGH Analysis Software (Vysis Inc, Downers Grove, IL). A
gain of DNA sequence copy number was defined by a
tumour/reference ratio >1.2 on both hybridizations. A copy number
decrease was defined as having a tumour/reference ratio below 0.8
on both standard and inverse hybridizations. In some situations the
tumour/reference ratio did not reach these thresholds but clearly
showed copy number alteration when compared to normal controls.
This may be due to sample heterogeneity or reduced dynamic range
of the metaphase spreads. In these situations the definition of a gain
was expanded to include situations when a tumour/reference ratio
minus 1 SD was greater than 1.0 and for losses where a
tumour/reference ratio plus 1 SD was less than 1.0 in both standard
and inverse hybridizations. No attempt was made to distinguish
between high-level copy number increases (amplifications) of
subregions as contrasted to gains of a whole arm. 
HPV methods 
HPV assays were performed to type HPV in the primary tumours.
HPV DNA was identified from a single slide by polymerase chain
reaction (PCR) with L1 consensus primers MY09 and MYI1 used
for amplification (Manos et al, 1989). Reactions underwent 40
cycles of amplification (Bauer et al, 1991; Leyton-Henry et al,
1996). DNA from cloned HPV 6, 11, 16, 18, 31 and 33 was used
as positive controls and DNA extracted from normal placenta as
negative controls. The positive HPV specimens were typed for
HPV 6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52 with type-specific
probes (Resnick et al, 1990). Specimen contamination and carry-
over were prevented by using positive displacement pipettes, prior
aliquoting of all reagents and performing pre- and post-PCR steps
in different rooms specifically allocated for PCR. In addition, to
avoid cross-contamination during sectioning of the blocks, the
microtome blades were changed, tweezers and cutting area were
carefully cleaned with xylene and ethanol between each block. 
Statistical analysis 
The Fisher’s exact test was used to compare proportions from 2
independent samples and McNemar’s test used for paired data.
The Wilcoxon test was used to test shift of location from 2 inde-
pendent samples and the Wilcoxon signed-rank test used for paired
data. All tests were 2-sided and results with a P value of less than
0.05 were considered statistically significant. The analyses were
carried out using StarXact version 4. 
RESULTS 
37 patients with squamous cell carcinoma of the cervix, with a
mean age of diagnosis of 48 years (range 30 to 68 years), were
studied. All the tumours were either histologic grade 2 or 3.
Recurrences of cervical cancer were seen in 9 women. Of these, 8
have died of disease, and one patient treated for vaginal vault
recurrence remains free of disease. Another woman died after
developing a primary lung cancer 6 years after treatment for her
cervical cancer and with no cervical recurrence. 3 patients who
died from cervix cancer had no lymph node metastases at the time
of diagnosis and 5 patients had metastases. The survival times
from diagnosis ranged from 12 to 45 months (mean 27 months).
There was an 85% 5-year survival rate for the study group with
lymph node metastases, and 71% 5-year survival for the group
with lymph node metastases. 
CGH was successfully performed on 32 primary tumours: 18 of
the 20 patients without lymph node metastases and 14 of the 17
patients with metastases. The individual ratio profile of a
representative case is seen in Figure 1. Tissue from lymph node
metastases was available for CGH analysis in 12 of the 17 patients
and was successful in 10 cases. The primary invasive carcinomas
had an average of 3.6 copy number changes per case, compared to
4.9 changes per case for lymph node metastases (P = 0.07). The
mean number of CGH changes seen in the primary tumours
grouped according to lymph node status is shown in Table 1. There
were significantly more CGH-detectable aberrations in the group
with lymph node metastases compared to the group without (P =
0.005), due to a significant increase in number of both gains and
losses (P = 0.02 and P = 0.03, respectively). However, when
primary cancers with lymph node metastases were compared to
their matched lymph node metastases, there was no statistical
difference in gains, losses or overall changes (Table 1). 
The most frequent chromosomal copy number changes in all
primary invasive cancers are shown in Figure 2. The most frequent
losses were on chromosome arm 3p (56%), 11q (47%), 6q (22%)
and 10q (16%) and the most frequent gain on 3q (44%). The
smallest regions of copy number alteration could be mapped to
loss of 3p14–22 and 11q22–24 and gain of 3q24–26. Table 2
shows the 4 chromosome arms most commonly altered in the
32 primary cervical tumours according to lymph node status.
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show that the occurrence of 3q gain was more frequent in the
primary cancers with lymph nodes metastases than those without
(64% versus 28%). When the lymph node metastases were
matched to the primary tumours, more 11q losses (80% versus
50%) and 6q losses (40% versus 29%) were found in the lymph
node metastases although again, this did not reach statistical
significance. No trends were noted between the two primary carci-
noma groups and the metastatic cancers for 3p loss. 
The CGH changes related to survival are shown in Table 3.
There were more overall DNA copy number changes in patients
who died of disease compared to survivors (4.4 versus 3.3). There
were more 3q gains and 3p and 6q losses in those that died of
disease. Interestingly, there were more 11q losses in the group that
survived. However, the small numbers of non-survivors in the
current study precluded definitive correlation between chromo-
somal copy number changes, sites of recurrent loss or gain and
overall survival. 
The HPV subtypes were determined in the 32 cervical tumours
on which CGH was successfully performed. The majority of
tumours were found to have moderate or high-risk subtypes. There
was no difference in absolute numbers of CGH detected gains or
losses or of chromosome region affected when HPV risk groups
were compared. 
DISCUSSION 
In this study we used CGH to analyse DNA copy number changes
associated with stage 1b cervix cancer with and without lymph
node metastases. We also studied the chromosomal alterations
within the lymph node metastases. The number of overall chromo-
somal copy number changes in our series of primary cervical
cancers is generally low compared to other cancers (Ried et al,
1994, 1995; Schrock et al, 1994), including our own series of
breast cancers (unpublished data). However, the low number of
changes is comparable with previous reports of similar stage-
matched cervical carcinomas (Heselmeyer et al, 1996; Dellas et al,
1999). There was a significant increase in chromosomal copy
number aberrations, including both gains and losses, in the
primary cancers with lymph node metastases compared to those
without metastases. The number of CGH-detected changes has
been shown to increase with stage of cervical cancer and poor
prognosis (Heselmeyer et al, 1997; Dellas et al, 1999). This
finding is analogous to other cancers, notably breast and kidney,
where a high overall number of genetic aberrations is associated
with poor prognosis (Isola et al, 1995; Moch et al, 1996). Since
patients with stage 1b cervical cancers have a worse prognosis
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Figure 1 A CGH ratio profile of a representative primary cervical cancer
case. Gains are represented to the right of the midline and to the right of the
ideogram and losses to the left of the midline and on the left of the ideogram 
Table 1 Lymph node status and mean CGH changes 
Gains Losses Total changes 
Primary tumour; without LN 0.5 2.1 2.6 
metastases (n = 18) 
Primary tumour; with LN 1.3 3.3 4.6 
metastases (n = 14) 
LN metastases (n = 10) 0.9 4 4.9 
LN = lymph node. 
12 3 4 5
6 7 8 9 10 11 12 X
13 14 15 16 17 18 19 20 21 22
Figure 2 Chromosome gains (right) and losses (left) in clinical stage 1b
primary cervical cancers 
Table 2 Common CGH changes in the primary cervical tumour according to lymph node status and in
the lymph node metastases
3p loss 11q loss 6q loss 10q loss 3q gain 
Primary tumours 18 (56%) 15 (47%) 7 (22%) 5 (16%) 14 (44%) 
overall (n = 32) 
Primary tumour; 9 (50%) 8 (44%) 3 (17%) 1 (6%) 5 (28%) 
without LN metastases 
(n = 18) 
Primary tumour with 9 (64%) 7 (50%) 4 (29%) 4 (29%) 9 (64%) 
LN metastases (n = 14) 
LN metastases (n = 10) 6 (60%) 8 (80%) 4 (40%) 3 (30%) 7 (70%) 
LN = lymph node. when lymph node positive (Martinbeau et al, 1982), the increased
number of changes in these cancers indicate that progressive geno-
typic aberrations are essential to tumour progression, similar to
cancers unassociated with virally-induced carcinogenesis. 
Several recurrent chromosomal aberrations have been described
for cervical cancer, detected either by CGH or allelic imbalance
(Hampton et al, 1994; Heselmeyer et al, 1996, 1997; Larson et al,
1997; Kersemaekers et al, 1998; Dellas et al, 1999; Kirchhoff et al,
1999). These regions include gain of 3q and losses of 3p, 11q, and
6q as observed in the current series. Gain of 3q was first reported
in the context of cervical cancer as a possible marker for the tran-
sition between severe dysplasia and invasive cancer (Heselmeyer
et al, 1996). However, a subsequent analysis has indicated that 3q
gain is a frequent occurrence even in pre-invasive cancers
(Kirchhoff et al, 1999). We show that in our stage-matched inva-
sive cancers, 3q gain was more frequent in the primary cervical
tumours with lymph node metastases when compared to those
without. Thus it would appear that gain of genetic material on 3q is
an important somatic event in cervical oncogenesis, but that its
acquisition is not restricted to a specific stage of development.
Interestingly, we were able to detect 3q gain more frequently by
CGH than in a recent study of similarly-staged cervical cancers
(44% versus 15%) (Dellas et al, 1999). However, cancers in this
latter study were tumour-enriched rather than microdissected as in
the present study, and thus it is possible that 3q gain in carcinoma
cells was obscured by contaminating normal cells. In this context
it is interesting to note that the same study was able to detect 3q
gain as frequently as 56% by FISH analysis, a figure similar to our
CGH-detected rate. 
Our analysis of cervical cancer was able to localize the smallest
area of gain on chromosome 3q to bands 24–26. A previous study
has defined the smallest region as 3q26–27 (Heselmeyer et al,
1997), making 3q26 a likely oncogene site important in cervical
carcinogenesis. Although there are several named genes mapped
to this area, perhaps the human telomerase RNA gene (mapped to
3q26.3) is the most interesting potential oncogene within this
region. We detected frequent DNA copy number loss on chromo-
some arm 3p, which has been previously documented by both
CGH and LOH studies (Heselmeyer et al, 1996; Larson et al,
1997; Wistuba et al, 1997; Steenbergen et al, 1998; Kersemaekers
et al, 1998; Dellas et al, 1999; Kirchhoff et al, 1999). Loss of 3p
appeared with similar frequency in both groups of primary cancers
and metastatic cancers. Indeed, this lack of discrepancy between
stage 1b primary cancer with and without metastases and
metastatic cancers is likely due to an important role of 3p loss
early in the pathogenesis of cervical cancer. Consistent with this
observation is the finding of frequent deletion of chromosome 3p
in pre-invasive cervical cancers detected by LOH analyses (Larson
et al, 1997; Wistuba et al, 1997). We were able to define the
smallest region of loss on 3p as 14–22. LOH studies have defined
3p14.2 and 3p21 as frequent areas of loss (Wistuba et al, 1997;
Kersemaekers et al, 1998). Several tumour suppressor genes have
been mapped to this region, including β -catenin. However, this
latter gene has effectively been excluded as a significant tumour
suppressor gene in cervical cancer (Kersemaekers et al, 1998).
Interestingly, a putative telomerase repressor gene has been
recently mapped to this region (3p 14.2–p21.1; Tanaka et al,
1998). 
Loss of genetic material on 11q was found in 47% of our stage
1b cervical carcinomas. Loss of 11q was also detected by CGH in
two other series of early-stage cervical carcinoma (Heselmeyer et
al, 1996; Dellas et al, 1999). We were able to map the smallest area
of loss to 11q22–24. The identical region has been previously
mapped by LOH as a putative site of a tumour suppressor gene
important in cervical cancer (Hampton et al, 1994). This region of
loss is also involved in carcinogenesis in other malignancies,
including breast, colorectal and ovarian cancers and malignant
melanoma and this region is known to harbour several candidate
tumour suppressor genes (Kersemaekers et al, 1998). 
Our study has identified progressive DNA copy number
changes associated with early-stage invasive cervical cancers with
and without lymph node metastases, a factor of potential prog-
nostic and therapeutic value. In addition, the data contribute
significantly to identifying sites of recurrent DNA gain and loss,
an important step in the localization of oncogenes and tumour
suppressor genes involved in the establishment and progression of
cervical cancer. 
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